{"id":"ast-001","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4779286","moleculeType":"Unknown","molecularWeight":"621.09"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AST-001 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly useful for treating type 2 diabetes.","oneSentence":"AST-001 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:46.564Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06333964","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children","status":"COMPLETED","sponsor":"Astrogen, Inc.","startDate":"2023-08-29","conditions":"Autism Spectrum Disorder","enrollment":169},{"nctId":"NCT06245330","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ascentawits Pharmaceuticals, Ltd","startDate":"2022-07-07","conditions":"Solid Tumor, Pancreatic Cancer","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AST-001","genericName":"AST-001","companyName":"Ascentawits Pharmaceuticals, Ltd","companyId":"ascentawits-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AST-001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}